Brand-name drug makers lose patent thicket weapon against generics
S. 2276 — ETHIC Act · Filed by Peter Welch (D-VT) · 2 cosponsors · Introduced Jul 15, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill limits pharmaceutical and biological product makers from suing generic drug applicants and biosimilar makers using multiple patents from the same patent family in a single lawsuit. Under current law, a brand-name drug company can assert many related patents against a generic competitor in one action; this bill caps that at one patent per 'Patent Group' (patents linked by double-patenting disclaimers). The restriction applies only to suits against generic/biosimilar applicants and manufacturers, effective immediately for new applications.
Why we flagged it
The bill's operative mechanism is a procedural limit on patent assertion in a specific litigation context (generic/biosimilar defense). It does not eliminate patents or invalidate them; it restricts the number of related patents a brand-name holder can assert in a single action against generic competitors. This is a targeted litigation reform, not a broad patent policy change.
What the text implies
- The definition of 'Patent Group' relies entirely on double-patenting disclaimers filed at the USPTO. Patent holders who have not filed such disclaimers may not be constrained by this rule, creating a potential loophole for companies that structure their patent portfolios differently.
- The one-patent-per-action limit does not prevent sequential suits against the same generic competitor using different patents from the same group—only the assertion of multiple patents in a single action. A brand-name holder could theoretically file separate actions, though this may trigger counterclaims or estoppel doctrines not addressed in the bill.
- The restriction applies only to suits against generic applicants and biosimilar licensees, not to suits against other competitors (e.g., over-the-counter manufacturers, foreign competitors, or non-pharmaceutical entities). Brand-name holders retain full patent assertion rights in other contexts.
- Applicability is prospective only (applications submitted after enactment). Pending litigation and applications filed before enactment are unaffected, limiting the immediate impact on existing patent disputes.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Generic and biosimilar drugs are the primary mechanism by which ordinary people access affordable medications after patent expiration. By restricting brand-name companies' ability to weaponize patent thickets against generic competitors, this bill reduces litigation costs that would otherwise be passed to consumers and accelerates market entry of lower-cost alternatives. The restriction is narrowly tailored to the generic/biosimilar context and does not eliminate patent rights—only the ability t
Who stands to gain
- generic pharmaceutical manufacturers
- biosimilar manufacturers
- pharmacy benefit managers (via lower drug costs)
- consumers (via lower medication prices)
Named in the bill
35 U.S.C. § 271(e), Federal Food, Drug, and Cosmetic Act § 505, Public Health Service Act § 351(k), 35 U.S.C. § 253 (double-patenting disclaimer), USPTO, generic drug manufacturers, biosimilar manufacturers, brand-name pharmaceutical companies
Where it stands
2 cosponsors: 1 Democrats, 1 Republicans.
- Jul 15, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Jul 15, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
28 lobbying clients named this bill on 99 disclosure filings across 6 quarters, Jun 2025 to Sep 2026. Those filings disclosed $152,025,170 in lobbying spend. A filing names 24 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 97% of bills with at least one filing.
Peter Welch, the sponsor, reported $51,500 in PAC receipts in the 2026 cycle.
- Pharmaceutical Research and Manufacturers of America — $44,050,000 on 5 filings
- Chamber of Commerce of the U.S.A. — $33,430,000 on 2 filings
- Amgen Inc — $11,720,000 on 4 filings
- Johnson & Johnson Services Inc — $11,160,000 on 5 filings
- Biotechnology Innovation Organization — $9,400,000 on 5 filings
Lobbying Disclosure Act filings through Oct 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (2,599 characters) on Sep 23, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 17,910 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2025 to Sep 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Oct 20, 2026 · page rendered 2026-11-22.
“Brand-name drug makers lose patent thicket weapon against generics” QuorumCivic. https://share.quorumcivic.app/bill/119/s2276 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.